Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Proposed MOFA budget hike seeks to counter China threat: Minister Lin
10/16/2025 12:30 PM - Science & Tech
Taiwan hospital debuts AI dialysis platform to boost efficiency, safety
10/16/2025 11:31 AM - Business
U.S. dollar down in Taipei trading
10/16/2025 10:38 AM - Business
Taiwan shares open higher
10/16/2025 09:11 AM - Society
Taiwan headline news
10/16/2025 08:47 AM